REDEFINE 1 obesity phase 3
A 2025 NEJM trial in 3,417 adults with overweight or obesity reported 20.4 percent body weight reduction against 3.0 percent on placebo over 68 weeks. Reported in the cited paper.
SourceBack to search
Weight LossMetabolicBlends
CagriSema
CagriSema is a fixed ratio combination of cagrilintide, an amylin analogue, and semaglutide, a GLP-1 agonist, in one weekly injection from Novo Nordisk. An application was filed in December 2025 and it is not yet approved in the United States or Europe.
- Lowest cost / mg
- $4.80/mg
- at Peptide Labs Inc
- Vendors listed
- 3
- In stock
- 6 of 6
- listings
- COA reports
- 3
Vendor listings
Compare CagriSema prices.
Show prices as
6 listings · CagriSema
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock20mgseen 4d ago
In stock5 mg · 10 vialsseen 3d ago
In stock10 mg · 10 vialsseen 3d ago
- Peptide Labs IncLowest $/mg
In stock20 mg · 10 vialsseen 3d ago
Overview
What is CagriSema?
CagriSema is a fixed ratio combination of cagrilintide, an amylin analogue, and semaglutide, a GLP-1 agonist, in one weekly injection from Novo Nordisk. An application was filed in December 2025 and it is not yet approved in the United States or Europe.
- Weight Management
- Appetite Control
- Dual Mechanism
- Glycemic Control
What the research reports
Reported benefits of CagriSema
Outcomes described across the published CagriSema literature and ongoing study. Read each as research context rather than a promised personal result.
- 01
Dual pathway weight effect
Combines amylin mediated satiety with GLP-1 receptor activation, reported to exceed the effect of either component used on its own. Reported in research settings.
- 02
Phase 3 weight loss outcomes
REDEFINE 1 reported 20.4 percent weight loss against 3.0 percent on placebo across 68 weeks in 3,417 adults with overweight or obesity. Reported in research settings.
- 03
Results in type 2 diabetes
REDEFINE 2 reported 13.7 percent weight loss against 3.4 percent on placebo in 1,206 adults who also had type 2 diabetes. Reported in research settings.
- 04
Blood pressure improvement
Analysis of REDEFINE 1 reported systolic blood pressure down 10.9 mmHg against 2.8 mmHg on placebo alongside the weight change. Reported in research settings.
- 05
Single weekly injection use
Delivering both agents in one fixed ratio pen removes the need to titrate and track two separate weekly protocols. Noted across the published research record.
Dosage and protocol
How CagriSema is typically studied
Trial protocols escalate both components together over roughly 16 weeks to a combined target of 2.4 mg cagrilintide with 2.4 mg semaglutide per weekly subcutaneous injection dose thereafter.
- Route
- Subcutaneous injection
- Example range
- 2.4 mg + 2.4 mg
- Frequency
- Once weekly
- Timing
- Once weekly on the same day, any time, with or without meals.
Clinical evidence
Clinical evidence for CagriSema
The published CagriSema record, labeled by strength so you can see what is settled and what is still emerging.
REDEFINE 2 diabetes trial
A 2025 NEJM trial in 1,206 adults with overweight or obesity and type 2 diabetes reported 13.7 percent weight reduction against 3.4 percent on placebo. Reported in the cited paper.
SourceBlood pressure safety analysis
A 2026 Hypertension analysis of REDEFINE 1 reported systolic blood pressure down 10.9 mmHg against 2.8 mmHg on placebo across the same 68 week period. Reported in the cited paper.
SourceInteractions
How CagriSema pairs with other peptides
- Semaglutide
- Already contains semaglutide, so adding a separate GLP-1 agonist duplicates the same receptor target.
- Tirzepatide
- Overlapping incretin activity. The two are not combined in any published clinical protocol.
- Insulin therapy use
- Combined glucose lowering raises hypoglycaemia risk and calls for supervised dose adjustment.
- Sulfonylureas
- Hypoglycaemia risk rises on combined therapy, so a prescribing review is the usual step. Confidence: emerging.
Questions
Frequently asked questions.
What is CagriSema?
CagriSema is a peptide compound used in research settings. It is commonly studied for its role in weight loss, metabolic, blends, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of CagriSema?
CagriSema is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does CagriSema work?
Like other research peptides, CagriSema is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is CagriSema for research use only?
Yes, products like CagriSema are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying CagriSema?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.
